Antiplatelets PowerPoint PPT Presentations

Anticoagulants and Antiplatelets Presenter: Dr. Ashish Chakravarty MD student Moderator: Dr. Kavita Sharma Professor Dept. of Anesthesiology and Intensive Care,

South East Asia - Optimising Reproductive & Child Health Outcomes in Developing Countries ... magnesium sulphate for eclampsia and pre-eclampsia ...

Clinical Trials. ESPS2 European Stroke Prevention Study 2 (1996) ... Clinical Trials. CAPRIE Clopidogrel vs Aspirin in Patients at Risk for Ischaemic Events (1996) ...

Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke TARDIS ISRCTN47823388 TARDIS Team Philip Bath, Margaret Adrian University of Nottingham

Early use in STEMI ('facilitated' PCI) ... ALBION: Clopidogrel 600 mg provides more rapid ... TITAN. GP, glycoprotein; PCI, percutaneous coronary intervention. ...

Anticoagulant Therapies, NSTE-ACS Guidelines, and Translation to Clinical Practice ACCF/AHA UA/NSTEMI Guidelines: Antiplatelets CCS NSTEMI Guidelines: Antiplatelets ...

Symptoms/Assessments Bleeding History of epistaxis Recent trauma or surgery N/V Hx of aspirin and/or antiplatelets meds Hx of HTN/atherosclerosis Erythema and ...

Fever associated with respiratory tract infection ... Antiplatelets: dypyramidole, ASA, Plavix. Antilipemics. Respiratory System: ...

... e.g. trimetazidine Anticoagulants & Antiplatelets Aspirin & Heparin decreasing the risk in unstable angina & acute coronary syndrome.

This session will focus on how we can commission, target and deliver medication ... Discontinue antiplatelets or PPIs inhibitors ...

Native renal biopsy in Scotland Is practice uniform? ... No differences in complications relating to age, renal function or gender ...

The global antiplatelet market was valued at $3.8 billion in 2022, and is projected to reach $5.8 billion by 2032, growing at a CAGR of 4.2% from 2023 to 2032. Antiplatelet drugs are the medications used to prevent or reduce the risk of blood clot formation by interfering with the activation or aggregation of platelets. These drugs work through various mechanisms. For example, ADP receptor inhibitors, such as clopidogrel and ticagrelor, block the adenosine diphosphate (ADP) receptors on platelets, preventing platelet activation and aggregation. Other medications Clopidogrel and Ticagrelor target specific receptors on platelets to prevent their activation and subsequent clot formation. These antiplatlet drugs reduce the risk of clot-related complications by keeping platelets from sticking together and forming clots.

Clopidogrel in STEMI for 1 month irrespective of the reperfusion strategy ... IV Otamixaban (SEPIA ACS trial) vs UFH in NSTEMI patients with planned PCI ...

Pharmacological management of post stroke patients By Khalid Khan Pharmacist HASU Plan Stroke- definition, classification-covered elsewhere Drug history and medicines ...

Chronic Kidney Disease and Diabetes ... DM 2 UKDPS 21% reduction in progression of nephropathy, ACCORD 32% reduction in nephropathy with lower HA1C ...

... prasugrel and ticagrelor Approved by SMC Place in therapy not clear May be alternative to clopidogrel as part of dual antiplatelet therapy Some benefits over ...

adjunctive antithrombotic to support PCI in addition to DAP heparin ... use of adjunctive therapy for PCI (beyond DAP) is evolving ...

Cost Containment Strategies CDR Denise M. Graham, MSC, USN PEC Director of Clinical Operations Objectives Outline DoD cost containment strategies used during the last ...

CHD: a definition. Coronary heart disease (or coronary artery disease) is a narrowing of the small ... The disease can cause chest pain (stable angina) ...

Methodological Considerations in Developing Hospital Composite Performance Measures Sean M. O Brien, PhD Department of Biostatistics & Bioinformatics

Unstable Angina and Non-ST elevation Myocardial Infarction John Blair, MD Unstable Angina / Non ST-Elevation Myocardial Infarction (UA/NSTEMI) Pathophysiology ...

The benefits of medication review for patients and practice based ... Bandolier www.jr2.ox.ac.uk/bandolier. 3. Casaburi R. Eur Respir J 2002;19:217 224 ...

Risk of bleeding per endoscopy or per digestive surgery depending of the treatment ... Temporary antithrombotic treatment high risk and not urgent endoscopy, ...

ACS is a major public health challenge In the US: Over 1.5 million people experience ACS annually1 In the EU: ACS is the most common cause of death, accounting for ...

Platelet Aggregation Inhibitors Professor. Dr. MAHMOUD KHATTAB,

Map of Medicine/ELIC Mr Paul Flora Consultant Vascular and General surgeon BLT Dominic Roberts GP Lower Clapton * * * Mode of operation of antiplatelet agents The ...

The patient with atrial fibrillation who needs PCI. The anticoagulant/antiplatelet conundrum. Kostadin Kichukov, MD, PhD City Clinic Sofia Department cardiology ...

Antiplatelet and anticoagulant therapy in stroke prevention Dr Sepehr Shakib Director Clinical Pharmacology Royal Adelaide Hospital Aspirin + Dipyridamole ...

Applied Clinical Sciences Lecture Programme Drugs affecting coagulation Dr Cathy Armstrong Anaesthetic SpR & Clinical Fellow in Undergraduate Medical Education

PAD patients suffer the highest rates of CV death, MI, and ischemic stroke ... Intermittent claudication with objective evidence of PAD (e.g. ABI 0.9) ...

Title: Renal Failure Acute and Chronic Author: Damon Smith Last modified by: Camille Scronce Created Date: 7/20/2006 6:31:19 PM Document presentation format

Guidelines for Prevention of Stroke in Patients with Ischemic Stroke or Transient Ischemic Attack From the Stroke Council of the AHA Ralph L Sacco, Chair; Robert ...

If you have any of the following symptoms, call for emergency help immediately. ... TIA symptoms are the same as the warning signs for stroke, but they last only a ...

Secondary Prevention of Ischemic Stroke or Transient Ischemic Attack Milan C. Mathew Resident in Internal Medicine Memorial Hospital of Rhode Island

of thrombophlebitis, abdominal & pelvic surgery, Obesity, neoplasms (lung), CHF, ... Exercise - Body wt. reduction - Eliminate smoking ...

... post-operative bleeding due to its vasoconstrictive properties-cocaine addicts ... 7) Proper physical properties (water solubility and stability in ...

Time to reperfusion 4 hr 1. HIGH RISK. TIMI risk score in NSTEMI. Age ... be used if hypotension occurs (w/o Base Hospital Physician order) and may be ...

... With Data Suggesting Efficacy Safe Herbals With Data Suggesting Efficacy Co-Enzyme Q-may decrease INR while on warfarin Chamomile-may increase INR if on ...

Stroke Core Rounds Mark Y. Wahba Preceptor: Dr. Ian Rigby Oct. 16th, 2003 WHO definition: Stroke a neurological deficit of sudden onset accompanied by focal ...

Health care needs assessment: the epidemiologically based needs ... Regular exercise. Diet and achieving a satisfactory weight. Reducing the intake of salt ...

Identify the uses and varying actions of these drugs. ... preparations include: ferrous fumarate, ferrous gluconate, ferrous sulfate, and iron dextran. ...

CLINICAL TRIAL UPDATE I Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF Trial Aldo P. Maggioni, Gianna Fabbri, Donata ...

Base (wider) is superior and under the 2nd rib. ... Starling's law. To a point the heart will pump out all blood it receives within certain limits. ...

To emphasise problems associated with their use especially WARFARIN ... 65 amino acid protein from medicinal leech forms tight 1:1 complex with ...

To emphasise problems associated with their use especially WARFARIN ... Warfarin blocks the vit K epoxide reductase step in this cycle. ...

Excellent oral activity in c. monkeys (ex-vivo) ... (Major Adverse Cardiac Event): Death, MI, ischemia requiring rehospitalization, ...

Systematic Hospital - based Secondary Prevention The Stroke PROTECT Program Preventing Recurrence Of Thrombo-embolic Events through Co-ordinated

Integrating Aggressive CV Risk Management in Primary Care ... Iliac crest. CDC Projections 2005 to 2050: Diabetes focus. Narayan KMV et al. Diabetes Care. ...

Class II Conflicting evidence and/or a divergence of opinion about the ... Hypertension: Pathophysiology, Diagnosis, and Management.2 ed. NY: Raven, 1995:127 ...

Pharmacology Update Which of the following is TRUE about intensive treatment of blood pressure and lipids in patients with type 2 diabetes? A.Most cardiovascular ...

Global myocardial infarction market size is expected to reach $2.68 Bn by 2028 at a rate of 7.1%, segmented as by drug class, antiplatelet agents, glycoprotein iib/iiia inhibitors

ISCHEMIA

The prime objective of this report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing with 10 major regions and 30 major countries. Deep researches and analysis were done during the preparation of the report.

Medical Conditions and Medications Impacting on Falls, Injury and Capacity to Exercise With thanks to Dr Rob Morris

Different Strokes for Different Folks Barb Bancroft, RN, MSN, PNP CPP Associates, Inc. www.barbbancroft.com Treatment of Ischemic/embolic strokes Prehospital care ...

vascular surgery